DrugPatentWatch Database Preview
Details for Patent: 8,062,665
Email this page to a colleague
Which drugs does patent 8,062,665 protect, and when does it expire?
Patent 8,062,665 protects PROMACTA and is included in one NDA.
Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-three patent family members in thirty-four countries.
Summary for Patent: 8,062,665
| Title: | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1- '-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| Abstract: | Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. |
| Inventor(s): | Muller; Francis X (King of Prussia, PA), Kapsi; Shivakumar G (King of Prussia, PA) |
| Assignee: | GlaxoSmithKline LLC (Philadelphia, PA) |
| Application Number: | 12/607,320 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Process; Use; |
Drugs Protected by US Patent 8,062,665
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-001 | Nov 20, 2008 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-002 | Nov 20, 2008 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-003 | Sep 8, 2009 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,062,665
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 059656 | ⤷ Try it Free | |||
| Argentina | 107711 | ⤷ Try it Free | |||
| Australia | 2007352608 | ⤷ Try it Free | |||
| Brazil | PI0721651 | ⤷ Try it Free | |||
| Canada | 2685831 | ⤷ Try it Free | |||
| Chile | 2007002242 | ⤷ Try it Free | |||
| China | 101686930 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
